The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, according to Marc N. Casper, chairman, president, and CEO of Thermo Fisher.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its ...

The acquisition of Solventum’s Purification & Filtration business will allow Thermo Fisher Scientific to enhance its ...

Thermo Fisher Scientific is buying Solventum’s purification & filtration unit for $4.1 billion in cash, strengthening its ...

Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides ...

Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company's $4.1 billion deal to sell its filtration ...

Thermo Fisher Scientific has a market capitalization of about $203.5 billion. Shares (NYSE: TMO) at midday Wednesday were trading around $532, which is near the bottom of their 52-week range.